US Patent 5,733,919: Scope of Claims and US Landscape Implications
US Patent 5,733,919 is directed to a specific pharmaceutical composition built around a defined small-molecule API (formula-bounded) plus a citrate buffer pH window (about 5 to 7) and a controlled tonicity adjustment range (about 50 to 500 milliosmoles). The claims are drafted in a way that concentrates protection on the formulation parameters rather than on method-of-use, assuming the underlying API structure is already known or independently patented.
What do the independent claim elements cover? (Claims 1 and 2)
Claim 1 (compositional system with formulation constraints)
Claim 1 covers a pharmaceutical composition comprising:
1) API component
- “A pharmaceutically effective amount” of a compound of the formula (represented in the claim text as ##STR8##) or pharmaceutically acceptable salts.
- Structural scope is governed by substituent parameters:
- R4 = aryl, C1-10 alkyl, or C1-10 arylalkyl
- R5 = ##STR9## where:
- R8 = hydroxy or C1-10 alkyloxy
- p = 0 or 1
- m = integer 2 to 6
2) Buffer system
- “A pharmaceutically acceptable amount of a citrate buffer” that is effective to provide pH between about 5 and 7.
3) Tonicity adjustment
- “Between about 50-500 milliosmoles of a tonicity adjusting agent.”
Practical read: Claim 1 is not limited to a single API variant; it covers a set of analogs that satisfy the parameterized formula, so long as they are formulated in the claimed citrate pH window and tonicity range.
Claim 2 (quantitative composition range)
Claim 2 further narrows claim 1 by specifying concentrations and ranges:
- API concentration: about 0.01 to 0.5 mg/mL
- Buffer: about 2–100 mM citrate buffer
- Tonicity: between about 50–500 milliosmoles
- Vehicle: water
Claim 2 is therefore a more operational formulation claim: it defines “how much” API, “how much” citrate, and “how much” tonicity adjustment to use.
What is the incremental narrowing across claims 3–5? (Dependent claim fenceposts)
Claim 3 (tight citrate and a specific tonicity value)
Claim 3 depends from claim 2 and narrows:
- API concentration: unchanged from claim 2 at about 0.01–0.5 mg/mL
- Citrate buffer: about 2–20 mM (narrower than 2–100 mM)
- Tonicity: about 290 milliosmoles (turns a range into a point value)
- Vehicle: water
Practical read: Claim 3 is a targeted embodiment around a specific tonicity target and a narrow citrate window, which tends to be how later commercial products get fenced.
Claim 4 (specific compound identity plus narrower dosage band)
Claim 4 depends from claim 3 and adds:
- The API is specifically identified as:
2-S-(n-Butylsulfonylamino)-3-4-(4-(piperidin-4-yl)butyloxy)phenyl!propionic acid
- API concentration: about 0.05 to about 0.25 mg/mL
- Citrate buffer: about 2–20 mM (consistent with claim 3)
Practical read: Claim 4 is an API-specific and dose band formulation claim. A product that uses a different salt form or different concentration outside that band can fall outside this dependent claim, even if it still hits claim 3’s broader parameterization (depending on claim construction and infringement theory).
Claim 5 (further pinpoints API, buffer, tonicity, and pH)
Claim 5 depends from claim 4 and pins:
- API concentration: about 0.25 mg/mL
- Citrate buffer: about 10 mM
- Tonicity adjusting agent: about 290 milliosmoles
- pH: about 6
Practical read: Claim 5 is the most commercially relevant “single-point” formulation claim. A competing formulation engineered to any of these values can avoid literal infringement of claim 5 (subject to doctrine-of-equivalents analysis, which is outside the scope of claim text).
How broad is the API portion, and where is the real claim leverage?
API scope is parameterized, not limited to one molecule
Across claims 1–3, the API is defined by a formula with substituent variables:
- R4 has broad latitude (aryl or C1-10 alkyl or arylalkyl).
- R8 provides a narrower choice (hydroxy or C1-10 alkyloxy).
- p toggles whether a specific structural element is present (0 or 1).
- m ranges 2 to 6.
This means claims 1–3 can cover multiple analogs, provided they still conform to all formula constraints.
Formulation conditions act as the gating mechanism
Even if the API scope is moderately broad, the claimed formulation constraints are tight and measurable:
- citrate buffer pH 5–7 (claim 1)
- citrate buffer concentration 2–100 mM (claim 2)
- citrate concentration 2–20 mM and tonicity about 290 mOsm (claim 3)
- plus the specific “commercial” embodiment values (claim 5)
Real leverage: A generic or biosimilar-type entrant can often stay within API-space but still must replicate the buffer/tonicity/pH architecture to land inside infringement of the dependent claims.
What parts of the claims are most likely to be litigated for infringement?
1) Tonicity adjustment value
- Claim 1: 50–500 milliosmoles (broad)
- Claim 3/5: about 290 milliosmoles (highly specific)
Tonicity is measurable and depends on the full formulation composition (including what counts as tonicity-adjusting agents and their contributions). For claim 3 and claim 5, “about 290” becomes a key boundary.
2) Citrate concentration and pH
- Claim 1: pH 5–7; citrate amount unspecified beyond “effective amount”
- Claim 2: citrate 2–100 mM
- Claim 3: citrate 2–20 mM
- Claim 5: citrate 10 mM and pH 6
A close variant that uses a different buffer (or a citrate concentration outside the band) can exit claim scope.
3) API concentration bands
- Claim 2: 0.01–0.5 mg/mL
- Claim 4: 0.05–0.25 mg/mL (for the specific named compound)
- Claim 5: 0.25 mg/mL exactly (about)
These bands matter for product commercialization: dose strength changes alone can avoid dependent-claim literal scope.
Claim scope map (from broad to narrow)
| Claim |
API |
API concentration |
Citrate buffer |
pH |
Tonicity |
| 1 |
Formula-defined compound (R4/R5 parameters) |
“Effective amount” |
Effective amount; citrate buffer |
5 to 7 |
50–500 mOsm |
| 2 |
Same formula-defined compound |
0.01–0.5 mg/mL |
2–100 mM |
(not specified) |
50–500 mOsm |
| 3 |
Same formula-defined compound |
0.01–0.5 mg/mL |
2–20 mM |
(not specified) |
about 290 mOsm |
| 4 |
Specific named compound |
0.05–0.25 mg/mL |
2–20 mM |
(not specified) |
(not specified but implied by claim 3) |
| 5 |
Same named compound |
about 0.25 mg/mL |
about 10 mM |
about 6 |
about 290 mOsm |
US patent landscape: what this claim structure implies for competitors
Why these claims are formulation-centric
The claims read like a composition patent that aims to block entry unless a challenger replicates:
- a narrow citrate buffering system
- a tonicity target
- and (for later dependent claims) a particular concentration and pH
This structure is common when a product is already known as an API, and exclusivity is pursued through reformulation and specific parameter ranges.
Where “design-around” is likely
Within this claim set, the most straightforward design-around levers are:
- use a non-citrate buffer or a citrate system outside the pH range for claim 1 (pH 5–7)
- keep API but adjust tonicity outside “about 290” to avoid claim 3 and claim 5
- shift citrate concentration outside the 2–20 mM band (claim 3/4) or outside 10 mM and pH 6 (claim 5)
- adjust dose strength outside 0.05–0.25 mg/mL (claim 4) or away from 0.25 mg/mL (claim 5)
Litigation posture likely depends on the product profile
- If the marketed product matches the “pinned” embodiment (claim 5 values), the patentee has a relatively clean literal infringement path.
- If the marketed product uses the broader parameters but not the pinned ones, the patentee may rely on claim 1 or claim 2, where ranges are wider and therefore easier to meet.
Scope of protection vs. patent exhaustion and continuation risk
The claims as provided show no method-of-treatment limitations, so the competitive risk is greatest for:
- direct sales of the same formulation (same composition parameters)
- distribution of a product that matches the claimed composition regardless of intended use
If there are later continuations or related patents in the same family (not provided here), those could add coverage around:
- additional pH or tonicity points
- additional salts or polymorphs
- alternate tonicity agents
- alternative concentrations or buffers
But based strictly on the claim text supplied, the immediate scope is the formulation parameter grid described above.
Key Takeaways
- US Patent 5,733,919 protects a pharmaceutical composition defined by a parameterized API formula plus citrate buffer pH 5–7 and tonicity 50–500 mOsm (claim 1), and tightens to citrate 2–20 mM with tonicity about 290 mOsm (claim 3).
- The strongest “pin” is claim 5: the named API at about 0.25 mg/mL, 10 mM citrate, pH about 6, and about 290 mOsm.
- From a landscape perspective, the likely competitive pressure point is whether a candidate product can match those measurable formulation targets; otherwise it can design around by moving buffer system, pH, tonicity, or concentration outside the dependent-claim bands.
FAQs
1) Is the API in claim 1 limited to a single compound?
No. Claim 1 uses a parameterized formula with variable definitions for R4, R8, p, and m.
2) What is the tightest tonicity specification in this claim set?
“about 290 milliosmoles” in claim 3 (and again in claim 5).
3) Does the patent require a specific pH for all claims?
No. Claim 1 requires pH about 5–7; claim 5 pins pH to about 6, while claims 2–4 do not specify a pH value in the text you provided.
4) What citrate concentration range matters most for the narrower claims?
Claim 3/4 require about 2–20 mM citrate buffer, while claim 5 requires about 10 mM.
5) What API concentration range is protected for the specifically named compound?
Claim 4: about 0.05 to about 0.25 mg/mL. Claim 5: about 0.25 mg/mL.
References
[1] US Patent 5,733,919. Claims 1–5 (as provided in the prompt).
